Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript

FG-3246 Phase II trial advances with 36% PSA50 response in monotherapy.

We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Every outlet that reported this, and when →

Read the original at fool.com →

More in Finance & Markets

More from Thursday 20 August →